About
Innovation
Team
Ethos
Careers
News
Publications
Contact
If we pull together collectively, we will achieve our goals
News
24.04.23
Medannex’s First-in-class Therapy Awarded UK ‘Innovation Passport’ to Accelerate Time to Market
01.03.23
MDX-124 receives Orphan Designation from the EMA for the Treatment of Pancreatic Cancer
03.01.23
Medannex features in global pharmaceutical publication ‘Scrip’
12.12.22
Regulators give green light to first-in-human study with MDX-124
08.04.22
Medannex’s first-in-class agent shows significant activity against clinically challenging cancers
21.01.22
Medannex’s monoclonal antibody MDX-124 highly active in pancreatic cancer models
1
2
3
4
5
»